GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » EV-to-Revenue

Exicure (Exicure) EV-to-Revenue : 0.38 (As of Apr. 26, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Exicure EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Exicure's enterprise value is $9.07 Mil. Exicure's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was $23.79 Mil. Therefore, Exicure's EV-to-Revenue for today is 0.38.

The historical rank and industry rank for Exicure's EV-to-Revenue or its related term are showing as below:

XCUR' s EV-to-Revenue Range Over the Past 10 Years
Min: -31.18   Med: 7.77   Max: 1060.82
Current: 0.38

During the past 7 years, the highest EV-to-Revenue of Exicure was 1060.82. The lowest was -31.18. And the median was 7.77.

XCUR's EV-to-Revenue is ranked better than
90.13% of 1033 companies
in the Biotechnology industry
Industry Median: 7.68 vs XCUR: 0.38

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Exicure's stock price is $0.5001. Exicure's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $4.79. Therefore, Exicure's PS Ratio for today is 0.10.


Exicure EV-to-Revenue Historical Data

The historical data trend for Exicure's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure EV-to-Revenue Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-Revenue
Get a 7-Day Free Trial 1,149.87 108.56 5.89 5.01 0.15

Exicure Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.12 -0.04 0.15 0.17 0.67

Competitive Comparison of Exicure's EV-to-Revenue

For the Biotechnology subindustry, Exicure's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exicure's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Exicure's EV-to-Revenue falls into.



Exicure EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Exicure's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9.066/23.79
=0.38

Exicure's current Enterprise Value is $9.07 Mil.
Exicure's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $23.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exicure  (NAS:XCUR) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Exicure's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.5001/4.788
=0.10

Exicure's share price for today is $0.5001.
Exicure's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.79.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exicure EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Exicure's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Exicure (Exicure) Business Description

Traded in Other Exchanges
Address
2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Executives
Minhee Eom director 2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko director 2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd. 10 percent owner 23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim director, officer: Chief Executive Officer, CFO 46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller director, officer: Chief Executive Officer, CFO 2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang director C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo director 2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin director 2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee director 2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul director 2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn director 2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc. 10 percent owner 3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar director C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077

Exicure (Exicure) Headlines

From GuruFocus

Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

By Business Wire Business Wire 05-27-2022